Moderna Soars 122% on Melanoma Vaccine Breakthrough, August 21

Moderna surged 122% to $139.76 on August 20 after announcing that its personalized mRNA vaccine reduced melanoma recurrence and spread in a Phase 3 trial of 1,137 patients. The vaccine, called Intismeran, was given alongside Merck’s immunotherapy drug Keytruda. This marks the first late-stage success for any mRNA cancer vaccine, a potential watershed moment for personalized cancer treatment.

How the vaccine works and what the trial showed

Intismeran is built from a sample of each patient’s own tumor. It trains the immune system to recognize specific mutations in that person’s cancer. In the trial, patients with high-risk melanoma who had surgery received either the vaccine plus Keytruda or Keytruda alone. Those who got both treatments stayed cancer-free longer and had lower risk of cancer spread, meeting both primary trial goals. Full data will be presented at an upcoming medical conference.

Why this matters for cancer treatment

Earlier data showed the combination reduced recurrence or death risk by 49% and distant spread or death risk by 59% versus Keytruda alone. For advanced stage three or four melanoma, five-year recurrence-free survival today runs around 20 to 35%. This vaccine could potentially double that rate. The approach is being tested for lung, breast, and pancreatic cancers as well.

Founders and executives see massive wealth gains

Moderna co-founder Robert Langer’s stake, estimated at 3%, jumped from $730 million to $1.7 billion. Co-founder Noubar Afeyan gained $184 million to reach $2.1 billion. CEO Stéphane Bancel’s wealth grew $2.5 billion to $4.8 billion. Investor Timothy Springer added $948 million to reach $2.2 billion. The stock had fallen to $22.28 on January 2 before this rally.

Meyka data shows caution despite the surge

Meyka grades MRNA a B with a hold recommendation, citing weak fundamentals. The stock trades at a negative P/E of -21.4 and negative ROE of -39%. RSI sits at 92, signaling overbought conditions. While five analysts rate it a buy and one rates it a sell, the company lost $7.96 per share last year. Meyka’s 12-month forecast is $58.61, well below the current price.

Final Thoughts

Moderna’s vaccine breakthrough is genuine, but the 122% rally has pushed the stock into overbought territory with weak underlying financials. Meyka’s B grade and $58.61 forecast suggest limited upside from current levels, even with regulatory approval still pending.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.